Amneal to Participate at Upcoming Investor Conferences in June
Amneal Pharmaceuticals (NASDAQ: AMRX) has announced its participation in two major investor conferences in June 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Amneal Pharmaceuticals (NASDAQ: AMRX) has announced its participation in two major investor conferences in June 2025. The company will present at the Jefferies Global Healthcare Conference on June 5 at 9:20 AM ET and participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 10 at 10:40 AM ET.
Co-CEO and President Chirag Patel and CFO Tasos Konidaris will represent Amneal at both events. Investors can access live webcasts through the company's investor relations website, with replay options available after the events.
Details
News Market Reaction – AMRX
The recorded move for AMRX in the trading session of this news was +0.27%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5, 2025, with company presentation at 9:20 AM ET, and Goldman Sachs Global Healthcare Conference on June 10, 2025, with fireside chat at 10:40 AM ET. Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Executive Vice President and Chief Financial Officer, will participate in both conferences. A live webcast will be accessible at https://investors.amneal.com with replays available following both events.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com and follow us on LinkedIn.
Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.